{
  "id": 9878163,
  "title": "China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts",
  "url": "https://urgent.news/2026/09/26/chinas-biotech-firms-move-up-value-chain-as-drug-deals-evolve-beyond-9878163",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-26T01:00:08.000Z",
  "source": {
    "name": "South China Morning Post",
    "slug": "south-china-morning-post",
    "url": "https://www.scmp.com/tech/tech-trends/article/3368781/chinas-biotech-firms-move-value-chain-drug-deals-evolve-beyond-licensing-analysts"
  },
  "original_language": "en",
  "account": null,
  "summary": "China's biotech firms are increasingly moving up the value chain by forming more significant drug development partnerships, according to analysts. This shift is evident in the latest deal between Chinese cancer drug developer InnoCare Pharma and US pharmaceutical giant Eli Lilly, which could be worth up to US$3.35 billion. This trend reflects China's transformation from a follower to a global innovation leader in biotechnology, as the country moves away from simply licensing individual drug candidates and towards co-development arrangements and broader platform partnerships. Analysts note that China's biotech sector is now generating innovative drug research at a higher quantity and quality, with recent deals like InnoCare's collaboration with Eli Lilly and Jiangsu Hengrui Pharmaceutical's agreement with Bristol Myers Squibb demonstrating this shift.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "SCMP Business",
        "title": "China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts",
        "url": "https://urgent.news/2026/09/26/chinas-biotech-firms-move-up-value-chain-as-drug-deals-evolve-beyond",
        "published": "2026-09-26T01:00:08.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}